BerGenBio
Clinical-stage biopharma that developed selective AXL kinase inhibitors for cancer.
BGBIO | OL
Overview
Corporate Details
- ISIN(s):
- NO0012921180 (+2 more)
- LEI:
- 213800TYYFXKYF3V2A23
- Country:
- Norway
- Address:
- MØLLENDALSBAKKEN 9, 5009 BERGEN
- Website:
- https://www.bergenbio.com/
- Sector:
- Manufacturing
Description
BerGenBio was a clinical-stage biopharmaceutical company focused on developing first-in-class selective AXL kinase inhibitors. The company's therapeutic candidates targeted AXL as a potential cornerstone of therapy for aggressive, advanced, and treatment-resistant cancers. In October 2025, BerGenBio completed a merger with Oncoinvent ASA, and the combined entity was renamed Oncoinvent.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-06-06 16:19 |
BERGENBIO PRESENTS CLINICAL DATA ON BEMCENTINIB IN COMBINATION WITH DOCETAXEL I…
|
English | 148.2 KB | ||
| 2022-06-06 16:18 |
BERGENBIO PRESENTS CLINICAL DATA ON BEMCENTINIB IN COMBINATION WITH DOCETAXEL I…
|
English | 3.7 KB | ||
| 2022-05-24 05:00 |
BERGENBIO ASA: RESULTS FOR THE FIRST QUARTER 2022
|
English | 6.8 MB | ||
| 2022-05-24 05:00 |
BERGENBIO ASA: RESULTS FOR THE FIRST QUARTER 2022
|
English | 159.7 KB | ||
| 2022-05-24 05:00 |
BERGENBIO ASA: RESULTS FOR THE FIRST QUARTER 2022
|
English | 6.1 KB | ||
| 2022-05-18 05:00 |
BERGENBIO ASA: INVITATION TO FIRST QUARTER 2022 RESULTS WEBCAST
|
English | 109.8 KB | ||
| 2022-05-18 05:00 |
BERGENBIO ASA: INVITATION TO FIRST QUARTER 2022 RESULTS WEBCAST
|
English | 2.7 KB | ||
| 2022-05-16 05:00 |
BERGENBIO TO PRESENT AT ABG SUNDAL COLLIER LIFE SCIENCE SUMMIT
|
English | 102.3 KB | ||
| 2022-05-16 05:00 |
BERGENBIO TO PRESENT AT ABG SUNDAL COLLIER LIFE SCIENCE SUMMIT
|
English | 1.7 KB | ||
| 2022-05-04 05:00 |
BERGENBIO ANNOUNCES LAUNCH OF BUSINESS STRATEGY FOCUSED ON NSCLC AND COVID-19
|
English | 159.1 KB | ||
| 2022-05-04 05:00 |
BERGENBIO ANNOUNCES LAUNCH OF BUSINESS STRATEGY FOCUSED ON NSCLC AND COVID-19
|
English | 8.4 KB | ||
| 2022-04-28 09:28 |
BerGenBio ASA: Minutes from the Annual General Meeting
|
Norwegian | 641.2 KB | ||
| 2022-04-28 09:28 |
BerGenBio ASA: Minutes from the Annual General Meeting
|
English | 1.6 KB | ||
| 2022-04-26 08:51 |
BERGENBIO TO PRESENT AT ARCTIC SECURITIES BIOTECH WEBINAR
|
English | 102.9 KB | ||
| 2022-04-26 08:51 |
BERGENBIO TO PRESENT AT ARCTIC SECURITIES BIOTECH WEBINAR
|
English | 2.2 KB |
Automate Your Workflow. Get a real-time feed of all BerGenBio filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BerGenBio
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BerGenBio via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
